- Q2 2024 Cue Biopharma Inc Earnings Call Transcript6 days ago€0.585 (+9.35%)Earnings
- Q4 2023 Cue Biopharma Inc Earnings Call TranscriptApr 08, 2024€1.7 (+4.94%)Earnings
- Q3 2023 Cue Biopharma Inc Earnings Call and Business Update TranscriptNov 09, 2023€2.24 (-4.36%)Earnings
- Q2 2023 Cue Biopharma Inc Earnings Call TranscriptAug 09, 2023€3.2 (+3.16%)Earnings
- Cue Biopharma Inc To Host Business Update Call TranscriptJun 14, 2023
- Cue Biopharma Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Cue Biopharma Inc at JMP Securities Life Sciences Conference TranscriptMay 15, 2023
- Q4 2022 Cue Biopharma Inc Earnings Call TranscriptMar 21, 2023€2.86 (+2.14%)Earnings
- Q3 2022 Cue Biopharma Inc Earnings Call TranscriptNov 14, 2022€3Earnings
- Q2 2022 Cue Biopharma Inc Earnings And Business Update Call TranscriptAug 23, 2022
- Cue Biopharma Inc at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Cue Biopharma Inc To Host Business Update And Ongoing CUE-101 Clinical Trials Call TranscriptJan 26, 2022
- Q2 2021 Cue Biopharma Inc Earnings Call TranscriptAug 17, 2021€8.45 (-8.65%)Earnings
- Q1 2021 Cue Biopharma Inc Earnings Call TranscriptMay 17, 2021€11.1 (+5.71%)Earnings
- Q4 2020 Cue Biopharma Inc Earnings Call TranscriptMar 16, 2021€12.5 (+5.93%)Earnings
- Cue Biopharma Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 04, 2021
- Cue Biopharma, Inc. - Special Call TranscriptNov 17, 2020
- Cue Biopharma Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Q2 2020 Cue Biopharma Inc Earnings Call TranscriptAug 31, 2020€14.7 (-1.34%)Earnings
- Q1 2020 Cue Biopharma Inc Earnings Call TranscriptMay 19, 2020€24Earnings
- Q4 2019 Cue Biopharma Inc Earnings Call TranscriptMar 17, 2020€11.6Earnings
- Cue Biopharma, Inc. - Special Call TranscriptNov 12, 2019
- Cue Biopharma Inc Investor Business Update TranscriptMay 21, 2019
- Cue Biopharma, Inc. - Special Call TranscriptMar 14, 2019
Cue Biopharma Inc at JMP Securities Life Sciences Conference Transcript
So good afternoon, everyone. It's my pleasure to welcome Cue Biopharma. Cue is one of our most interesting companies working in the immunotherapy space, really trying to harness the power of IL-2.
And so here to tell us about the company is CEO, Dan Passeri; CSO, Anish. And go ahead and give us a little bit of an update, obviously, on the company. And then we'll jump into some questions.
Okay. Thanks, Ren. Really appreciate it and welcome, everyone. I also want to thank JMP Securities for giving us an opportunity to present. We'll have few forward-looking statements in the presentation.
So as was stated, our overall vision is to basically deploy in the first case, IL-2. And it's harnessing what we call nature's cues. That's where the company's name comes from.
What we mean by that is the signals that nature has evolved and deploys to modulate the immune system in a highly selective relevant manner. We've basically taken an approach to engineer
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)